ÂÜÀòÂÒÂ×

Michael Bonney is the current Chair of Kaleido Biosciences' Board of Directors, a clinical-stage healthcare company leveraging the microbiome to treat disease and improve human health; previously he served as the company's CEO. Bonney is the former president and CEO of Cubist Pharmaceuticals, which, under his leadership, grew into a leading antibiotic company and was acquired by Merck. Prior to Cubist, he held leading roles at Biogen and Zeneca Pharmaceuticals. Bonney chairs the boards of Alnylam Pharmaceuticals and Magenta Therapeutics and serves on the board of Bristol Myers Squibb.